Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers. | Front Oncol;8: 423, 2018. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers.

Komiya, Takefumi; Huang, Chao H.

Affiliation

Komiya T; Parkview Cancer Institute, Fort Wayne, IN, United States.
Huang CH; Division of Medical Oncology, University of Kansas Medical Center, Fairway, KS, United States.

Front Oncol ; 8: 423, 2018.

Article in En | MEDLINE | ID: mdl-30338242

Key words

IDO (indoleamine 2,3-dioxygenase); IDO1 inhibitor; PD-1; clinical trials as topic; immuno-oncology; tryptophan

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Oncol Year: 2018 Document type: Article Affiliation country: United States Country of publication: Switzerland

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Oncol Year: 2018 Document type: Article Affiliation country: United States Country of publication: Switzerland